abstract |
Chronic obstructive pulmonary disease is treated with a selective ET A receptor antagonist such as 4-(7-ethyl-1,3-benxodioxol-5-yl)-2-[2-trifluoromethyl)phenyl]-2H-1,2-benzothiazine-3-carboxylic acid 1,1-dioxide or a pharmaceutically acceptable salt thereof. |